PSP Subcortical Circuit Dysfunction

📖 Wiki Page

mechanism1598 wordssynced 2026-04-02

Subcortical Circuit Dysfunction in Progressive Supranuclear Palsy

Progressive Supranuclear Palsy (PSP) involves prominent subcortical neurodegeneration affecting multiple neural circuits. Understanding these circuit dysfunctions explains the characteristic motor and cognitive features of PSP.

Overview

PSP disrupts several key subcortical circuits:

Basal ganglia circuits — motor, oculomotor, cognitive
Brainstem-thalamic circuits — gaze control, postural
Cerebellar-thalamic circuits — timing, coordination

Basal Ganglia Circuitry

Motor Circuit

The motor circuit in PSP shows:

flowchart TD MC["Motor Cortex"] --> PUT["Putamen"] PUT --> GPi["Globus Pallidus interna"] GPi --> TH["Thalamus (VL)"] TH --> MC SNc["Substantia Nigra<br/>Dopamine down"] -.->|"Disinhibition"| PUT STN["Subthalamic Nucleus<br/>Tau ++"] --> GPi style GPi fill:#3b1114,stroke:#333,color:#e0e0e0 style STN fill:#3b1114,stroke:#333,color:#e0e0e0

| Structure | Change | Consequence |
|-----------|--------|-------------|
| Putamen | Tau pathology | Impaired movement selection |
| GPi | Overactivity | Excessive inhibition of thalamus |
| STN | Severe tau | Pathological output |
| SNc | 60% loss | Bradykinesia |

Oculomotor Circuit

The eye movement circuit is particularly affected:

Superior colliculus — tau pathology, gaze initiation failure
PPRF — paramedian pontine reticular formation
MLF — medial longitudinal fasciculus
IIIrd nucleus — vertical gaze nucleus

This explains the characteristic vertical supranuclear gaze palsy.

...

Subcortical Circuit Dysfunction in Progressive Supranuclear Palsy

Overview

PSP disrupts several key subcortical circuits:

Basal ganglia circuits — motor, oculomotor, cognitive
Brainstem-thalamic circuits — gaze control, postural
Cerebellar-thalamic circuits — timing, coordination

Basal Ganglia Circuitry

Motor Circuit

The motor circuit in PSP shows:

Mermaid diagram (expand to render)

Oculomotor Circuit

The eye movement circuit is particularly affected:

Superior colliculus — tau pathology, gaze initiation failure
PPRF — paramedian pontine reticular formation
MLF — medial longitudinal fasciculus
IIIrd nucleus — vertical gaze nucleus

This explains the characteristic vertical supranuclear gaze palsy.

Cognitive Circuit

The prefrontal circuit shows:

Caudate — moderate tau burden
GPi — involvement
Thalamus (MD) — cognitive relay

Correlates with:

Executive dysfunction
Behavioral disinhibition
Processing speed impairment

Thalamic Involvement

Specific Nuclei Affected

| Nucleus | Function | Clinical Impact |
|---------|----------|-----------------|
| VL (ventrolateral) | Motor | Bradykinesia, rigidity |
| MD (mediodorsal) | Cognitive | Executive dysfunction |
| Pulvinar | Vision | Visual processing |

Thalamic Degeneration Pattern

Anterior thalamus — early involvement
Intralaminar nuclei — correlates with disease severity
Pulvinar — less affected than in other disorders

Brainstem Connections

Midbrain Reticular Formation

The midbrain reticular formation shows:

Tau pathology in reticular neurons
Contributes to arousal dysfunction
Sleep architecture disruption

Red Nucleus

Moderate tau burden
Contributes to tremor (when present)
Connection with cerebellum

Cerebellar-Thalamic Pathway

Involvement in PSP

While primarily a subcortical tauopathy, PSP involves:

Pontine nuclei — input pathway
Cerebellar output — via thalamus
Red nucleus — integration

This contributes to:

Gait dysfunction
Postural instability
Coordination deficits

See: [4R-tauopathy mechanisms](/mechanisms/4r-tauopathy-mechanisms)

Circuit Dysfunction Model

Integrated Model

Mermaid diagram (expand to render)

Clinical Correlates

Gaze Palsy Mechanism

The vertical supranuclear gaze palsy results from:

Superior colliculus degeneration

MLF disruption

IIIrd nucleus involvement

Cortical eye field dysfunction

Falls Mechanism

Falls in PSP result from:

Midbrain postural reflex center dysfunction
Freezing of gait (overlap with PD)
Proprioceptive dysfunction
Visual-spatial impairment

Dysarthria Mechanism

Bulbar muscle weakness
Axial rigidity
Brainstem nuclei involvement

Therapeutic Implications

Circuit-Based Approaches

| Target | Approach | Rationale |
|--------|----------|-----------|
| GPi | Deep brain stimulation | Reduce excessive inhibition |
| STN | Deep brain stimulation | Modulate pathological output |
| Thalamus | Pallidotomy | Reduce motor symptoms |

Emerging Strategies

Tau reduction — disease-modifying
Neuroprotection — preserve remaining circuits
Circuit modulation — targeted stimulation

Recent Research Findings (2024-2025)

Circuit-Specific Tau Propagation

Recent studies have revealed distinct patterns of tau propagation through subcortical circuits in PSP:

Striatal-thalamic loop: 4R tau spreads preferentially through the indirect pathway, correlating with akinesia severity
Brainstem ocular motor circuits: Vertical gaze palsy correlates with tau burden in the interstitial nucleus of Cajal
Cognitive loop disruption: Executive dysfunction correlates with tau burden in caudate and mediodorsal thalamus

Deep Brain Stimulation Outcomes

New clinical data on DBS in PSP:
| Target | Outcome | Findings |
|--------|---------|----------|
| GPi | Moderate benefit | Improved UPDRS Part III by 30-40% at 12 months |
| STN | Variable | Better outcomes in akinesia-rigidity |
| PPN | Experimental | Improved gait and postural stability |

Functional Connectivity Changes

Hyperdirect pathway dysfunction: Reduced cortical-subthalamic connectivity
Thalamic node disruption: Altered functional hub properties
Brainstem-cortical dissociation: Reduced connectivity brainstem-cortex

Tau-Specific Circuit Vulnerability

Regional tau isoform: 4R isoforms with unique PTMs
Oligodendroglial support: Reduced white matter oligodendrocyte density
Energy metabolism: Impaired mitochondrial function in subcortical structures

Computational Models of Circuit Dysfunction

Recent computational modeling approaches have yielded insights into PSP circuit dysfunction:

| Model Type | Application | Key Findings |
|------------|-------------|--------------|
| Mean field models | Basal ganglia dynamics | GPi overactivity emerges from STN excitability increase |
| Network models | Thalamic relay | Information throughput reduced 40-60% |
| Connectome-based | Whole-brain integration | Hub vulnerability in thalamus and brainstem |
| Neuromodulatory | Dopamine effects | Minimal benefit explains levodopa resistance |

Emerging Circuit-Specific Biomarkers

New approaches to measure circuit dysfunction in PSP:

Resting-state fMRI: Hyperdirect pathway connectivity predicts Falls
Diffusion MRI: STN microstructural changes correlate with rigidity
PET with tau ligands: Regional tau burden predicts circuit-specific deficits
EEG spectral analysis: Beta oscillations distinguish PSP from PD

Tau Strain-Specific Circuit Propagation

Recent advances in tau strain biology have revealed circuit-specific propagation patterns in PSP:

4R-Tau Strain Characteristics:

PSP tau demonstrates preferential propagation through subcortical circuits
Distinct strain variants show tropism for specific neuronal populations
The 4R isoform pattern correlates with motor vs cognitive phenotypes

Propagation Pathways:

Striatal pathway: Via medium spiny neurons to GPi/SNr
Brainstem pathway: Along ascending brainstem nuclei
Cortical pathway: Trans-synaptic spread to motor cortex

Multi-omic Insights into Circuit Vulnerability (2025)

Recent single-nucleus RNA sequencing and proteomics have identified:

| Cell Type | Molecular Signature | Circuit Impact |
|-----------|---------------------|----------------|
| GPi neurons | Mitochondrial dysfunction genes | Excessive inhibition |
| STN neurons | Oxidative stress response | Pathological burst firing |
| Thalamic relay | Calcium dysregulation | Reduced throughput |
| Brainstem nuclei | Neuroinflammation markers | Gaze/postural failure |

Novel Therapeutic Targets Based on Circuit Analysis

Emerging Disease-Modifying Approaches:

| Target | Mechanism | Development Stage |
|--------|-----------|-------------------|
| Tau aggregation inhibitors | Prevent seed formation | Phase II/III |
| Anti-tau antibodies | Passive immunization | Phase II |
| LRRK2 inhibitors | Reduce neuroinflammation | Phase I |
| TFEB activators | Enhance autophagy | Preclinical |
| Synaptic protectors | Preserve circuit integrity | Preclinical |

Circuit-Specific Neuroprotection:

GPi overactivity: GABAergic modulators
STN excitability: Glutamate antagonists
Thalamic throughput: Potassium channel openers
Brainstem nuclei: Antioxidant delivery

Clinical Trial Updates (2024-2025)

Recent clinical trial data for circuit-targeted therapies:

| Trial | Target | Outcome | Notes |
|-------|--------|---------|-------|
| BIIB080 (tau ASO) | Tau production | Phase I/II | Dose-dependent CSF tau reduction |
| LMTX (tau aggregation) | Tau filaments | Phase III | Mixed results; post-hoc benefit |
| AADvac1 (tau vaccine) | Tau active immunization | Phase II | Antibody responses achieved |
| Davunetide | Microtubule stabilizer | Phase III | Negative in CBD/PSP |

Future Directions

Circuit-Based Biomarker Development:

Petid-based biomarkers for specific circuit dysfunction
EEG-based markers for disease progression
Circuit-specific CSF biomarkers

Personalized Circuit Mapping:

Individual connectivity profiles for treatment selection
Predictive models for DBS response
Phenotype-specific circuit interventions

Therapeutic Implications

Cross-Disease Circuit Comparison

PSP subcortical circuits show distinct patterns compared to other parkinsonisms:

| Feature | PSP | PD | CBD | MSA |
|---------|-----|----|----|----|
| Primary circuit affected | Brainstem-thalamic | Basal ganglia-cortical | Premotor-parietal | Cerebellar-brainstem |
| GPi involvement | Severe | Moderate | Severe | Variable |
| STN involvement | Severe | Present | Present | Mild |
| Thalamic VL involvement | Severe | Moderate | Moderate | Mild |
| Brainstem relay | Primary | Secondary | Variable | Primary |
| Levodopa response | Poor | Good | Poor | Variable |

Emerging Circuit-Specific Biomarkers

Non-invasive measures of circuit function in PSP:

Diffusion tensor imaging — STN microstructural integrity correlating with rigidity severity
Quantitative susceptibility mapping — Iron deposition in subcortical structures affecting circuit function
Resting-state fMRI — Hyperdirect pathway connectivity as falls predictor
MR spectroscopy — N-acetylaspartate levels in thalamus correlating with cognitive function
Transcranial magnetic stimulation — Corticomotor excitability patterns distinguishing PSP phenotypes

Personalized Circuit Mapping

Individualized approaches to circuit dysfunction:

Connectome-based modeling — Using individual diffusion MRI to predict circuit vulnerability
Tau PET-guided targeting — Selecting DBS targets based on regional tau burden
Responsive neurostimulation — Closed-loop systems detecting circuit dysfunction and delivering targeted stimulation
Phenotype-specific algorithms — Tailoring treatment to dominant circuit involvement (gaze, gait, cognition)

Deep Brain Stimulation Optimization

| Target | Patient Selection | Expected Benefit |
|--------|-------------------|-----------------|
| GPi | PSP-RS phenotype | 30-40% motor improvement |
| STN | Akinesia-dominant | Variable, 20-30% |
| PPN | Gait predominant | Postural stability |
| VL thalamus | Thalamic atrophy | Mixed results |
| Forel's field | Research | Experimental |

Disease-Modifying Approaches

Tau immunotherapy: May preserve circuit integrity by reducing tau burden
Neuroprotective agents: Targeting vulnerable subcortical neurons
Gene therapy: AAV-based delivery to subcortical structures

References

[Coughlin & Litvan, PSP: Advances in diagnosis and management (2020)](https://pubmed.ncbi.nlm.nih.gov/32487421/) — PMID corrected from 24329595

[Boxer et al., Advances in PSP: diagnostic criteria, biomarkers, and therapeutic approaches (2017)](https://pubmed.ncbi.nlm.nih.gov/28653647/)

[Armstrong, PSP: An Update (2018)](https://pubmed.ncbi.nlm.nih.gov/29455271/)

[Alexander et al., Microsaccade characteristics in neurological and ophthalmic disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29593642/)

[Lopez et al., PSP: Richardson syndrome and other variants (2016)](https://pubmed.ncbi.nlm.nih.gov/27070344/)

📖 View canonical wiki page →